

**Supplementary Table 2.** Clinical parameters at baseline and the changes that occurred from baseline (ADD-ON vs. fibrate-untreated control)

Variable	ADD-ON (n=166)	Mean change at 52 weeks (95% CI)	Control (fibrate-untreated) (n=183)	Mean change at 52 weeks (95% CI)	P value
eGFR, mL/min/1.73 m <sup>2</sup>	69.6±20.0	-1.7 (-3.2 to -0.2) <sup>a</sup>	69.5±23.3	-0.9 (-2.1 to 0.4)	0.4200
BMI, kg/m <sup>2</sup>	27.7±4.4	-0.04 (-0.18 to 0.09)	27.6±4.7	-0.07 (-0.22 to 0.09)	0.8091
TC, mg/dL	187.4±35.8	-7.1 (-11.1 to -3.1) <sup>c</sup>	188.7±35.4	-1.6 (-6.0 to 2.8)	0.0712
TG, mg/dL	199 (155–273)	-77 (-330 to 32) <sup>c</sup>	191 (160–233)	-11 (-106 to 165)	<0.0001
HDL-C, mg/dL	51.1±12.1	2.8 (1.4 to 4.1) <sup>c</sup>	50.0±12.3	0 (-1.0 to 0.9)	0.0006
FPG, mg/dL	141.6±39.0	-5.8 (-10.9 to -0.7) <sup>a</sup>	140.1±34.8	0.5 (-4.4 to 5.5)	0.0816
HbA1c, %	7.2±0.9	0.05 (-0.06 to 0.17)	7.2±0.9	-0.01 (-0.13 to 0.11)	0.4690
AST, IU/L	25 (20–36)	-2 (-24 to 18) <sup>b</sup>	24 (19–33)	0 (-18 to 14)	0.0201
ALT, IU/L	32 (20–46)	-7 (-42 to 12) <sup>c</sup>	29 (19–41)	-1 (-25 to 23)	<0.0001
γ-GTP, IU/L	45 (25–76)	-16 (-101 to 4) <sup>c</sup>	41 (26–60)	-1 (-42 to 27)	<0.0001
UA, mg/dL	5.8±1.4	0.04 (-0.11 to 0.19)	5.7±1.4	-0.09 (-0.21 to 0.04)	0.1957

Values are presented as mean ± standard deviation, median (interquartile range), or mean change (95% CI). The significance of differences in the changes from baseline to 52 weeks between the ADD-ON group and control group was examined using an unpaired *t*-test or the Mann-Whitney *U* test.

CI, confidence interval; eGFR, estimated glomerular filtration rate; BMI, body mass index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; UA, uric acid.

<sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01, <sup>c</sup>*P*<0.001 vs. each baseline.